Results 71 to 80 of about 103,365 (348)

A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction

Advanced Science, EarlyView.
Obesity involves chronic inflammation and mitochondrial dysfunction. This study identifies cytochrome P450 2E1 (CYP2E1) as a novel inflammatory target in adipose tissue. Its activity increases in obese mice and correlates with inflammation and mitochondrial impairment.
Jinhuan Qiu, Liyuan Gao, Liyang Wang, Xueke Wang, Lin Jia, Mengyan Deng, Liming Tang, Qiang Wen, Na Gao, Haiwei Xu, Hailing Qiao   +10 more
wiley   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Caspase‐3/GSDME‐Mediated Trophoblast Pyroptosis and Reciprocal Macrophage Polarization Contribute to Inflammation in Early‐Onset Preeclampsia

Advanced Science, EarlyView.
In trophoblast cells, T/S (TNFα + SM164) activated caspase‐3, which cleaved GSDME to switch apoptosis to pyroptosis, causing cell swelling, membrane rupture, and release of LDH, HMGB1, IL‐1β and IL‐18. These cytokines induced pro‐inflammatory macrophage polarization, which in turn reinforced pyroptotic signaling in trophoblasts, amplifying systemic ...
Baoying Huang, Weinan Deng, Shilei Bi, Yifan Wang, Zhaowei Tu, Lijun Huang, Lili Du, Lizi Zhang, Zhoushan Feng, Wei Sun, Tengfei Liu, Julia Kzhyshkowska, Haibin Wang, Jingsi Chen, Dunjin Chen, Shuang Zhang   +15 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor expression in the human eye [PDF]

Diabetes, Obesity and Metabolism, 2018
Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo.
Josephine B. Hebsgaard, Charles Pyke, Emre Yildirim, Lotte B. Knudsen, Steffen Heegaard, Peter H. Kvist   +5 more
openaire   +4 more sources

The Gut Commensal Butyricimonas Virosa Modulates Gut Microbiota‐Dependent Thiamine Metabolism and Attenuates Mouse Steatotic Liver Disease

Advanced Science, EarlyView.
This study reveals that dietary stachyose enriches Butyricimonas virosa, effectively attenuating metabolic dysfunction‐associated steatotic liver disease (MASLD). Mechanistically, B. virosa enhances gut thiamine monophosphate synthesis, which elevates hepatic thiamine pyrophosphate levels.
Ningning He, Haoyu Wang, Zizhen Yang, Hui Li, Bei Liu, Kaiwei Chen, Zhinan Wu, Xinnan Zhao, Hewei Liang, Mengmeng Wang, Xiaofang Li, Yiyi Zhong, Haifeng Zhang, Liang Xiao, Karsten Kristiansen, Jixing Peng, Yuanqiang Zou, Shangyong Li   +17 more
wiley   +1 more source

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst, Al-Sabah, Baggio, Beinborn, Biasini, Chen, Chen, Cheng, Coopman, Dan Donnelly, DeFronzo, Di Paolo, Donnelly, Drucker, Hoang, Hollenstein, Inooka, Kieffer, Knudsen, Koole, Koole, Koole, López de Maturana, López de Maturana, Mann, Mann, Mayo, Miller, Monaghan, Moon, Parthier, Perret, Pioszak, Rachel L. Dods, Roberts, Rodrigues, Runge, Runge, Sanchez, Siu, Solano, Tibaduiza, Turton, Underwood, Vertongen, Vilardaga, Wettergren, Wootten, Xiao, Yang, Ørskov   +50 more
core   +1 more source

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

Advanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma, Yunxuan Liu, Huijuan Zhang, Yian Fang, Yizhe Xue, Junsheng Xue, Ziqiong Jiang, Tianyan Zhou, Yanyun Hao, Fei Xie, Lei Miao   +10 more
wiley   +1 more source

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes [PDF]

Endocrinology and Metabolism, 2017
It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM).
Won-Young Lee
doaj   +1 more source

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. [PDF]

, 2012
Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and
Butler, Peter C, Dawson, David, Dry, Sarah M, Gier, Belinda, Kirakossian, David, Matveyenko, Aleksey V   +5 more
core   +1 more source

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source